He & She MD Review: Questions to Settle Before Choosing a GLP-1 Plan

01Who would be responsible for your care?

Start by separating the brand from the clinical practice. The FAQ identifies Wasef Health, PC, care of Michael Wasef MD, as the clinical provider. It supplies contact@wasef-health.com and an office address at 5260 78th Ave N, PO Box 1697, Pinellas Park, Florida. The plans page separately presents Ozita Cooper, MD, as chief medical officer and describes her as dual board-certified in obesity and emergency medicine. These are site statements; this review did not independently verify those credentials.

The terms, carrying a November 1, 2022 revision date, describe a different organizational arrangement. They say He and She MD provides a technology platform rather than medical services and connects patients with professionals employed or contracted by Beluga Health, P.A., or similar affiliated entities. The consulted documentation does not resolve which entity currently handles each service or how Wasef Health and Beluga responsibilities relate.

Before providing medical information, ask for the name of the practice treating you, the prescribing clinician and the contact route for clinical concerns. Also ask which documents govern that relationship today. This is not a reason to assume the advertised service is unavailable; it is a reason to identify the accountable practice. Our program-fit questions can help organize that conversation without treating a brand name as a substitute for a care agreement.

02What happens between the questionnaire and a prescription?

He & She MD advertises a free online assessment taking about five minutes. The questionnaire asks about goals and medical history, and the site says a licensed, board-certified U.S. physician or DO reviews it. A separate process graphic estimates provider review at approximately 24 hours. The five-minute figure describes completing the assessment, not the duration of a consultation, a guaranteed clinical decision or delivery of medication.

The terms require users to be at least 18, located in a state where the relevant service operates and willing to accept the terms. An educational page discusses BMI of 30 or higher, or 27 or higher with certain weight-related health problems, while emphasizing individualized eligibility. Those thresholds do not guarantee admission or a particular prescription. The plans page says patients are charged only if medication is prescribed and pay nothing if they are not candidates.

Useful intake questions concern the actual encounter: Will there be a live conversation if needed? Are initial or periodic laboratory tests required, and who pays? What happens if the clinician needs more information? The consulted pages do not establish laboratory requirements or costs. NIDDK advises discussing medicines, supplements, allergies and pregnancy plans with the clinician; that conversation is more informative than relying on a short eligibility quiz alone.

03Which medication and presentation would you actually receive?

The advertised choices are broader than one standard injection program. Product pages describe subcutaneous semaglutide and once-weekly subcutaneous tirzepatide, along with semaglutide and tirzepatide tablets for people preferring a noninjectable option. The plans page also mentions Wegovy, Ozempic, Zepbound and Mounjaro when clinically appropriate and available. It does not establish that branded medicines share the compounded-plan prices or are equally available to every applicant.

The oral pages need particularly careful clarification. Their exact formulations, added ingredients, manufacturers and product-specific regulatory status are not established in the consulted documentation. Their pricing tables also carry inconsistent labels: the oral semaglutide page says “Semaglutide Injectable Pricing,” while the oral tirzepatide page says “Sermorelin Injectable Pricing.” Ask for a written identification of the medicine, route, formulation, dispensing pharmacy and applicable price rather than assuming the surrounding page resolves those errors.

FDA approval belongs to a specific product, not a clinic, pharmacy or ingredient in every formulation. Compounded preparations are not FDA approved or subject to FDA premarket review for safety, effectiveness and quality; that alone does not establish clinical inequivalence. FDA recommends them when an individual's medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. Our medication-identification questions offer a practical checklist for discussing these distinctions.

04Which advertised price would appear at checkout?

The plans page offers several payment schedules rather than one mandatory prepayment arrangement. For compounded semaglutide, it lists $199 billed monthly, $447 every three months, $834 every six months or $1,188 annually. Compounded tirzepatide is listed at $299 monthly, $627 every three months, $1,194 every six months or $1,908 annually. The monthly equivalents for longer plans are not separate month-to-month payment promises.

Individual injectable pages publish higher nonannual monthly figures, as the table shows. The semaglutide page explicitly conditions its starting price of $99 per month on purchasing 12 months of supply. It also advertises the same price at every dose, no membership fee, no insurance requirement and HSA/FSA acceptance. Ask which page controls your transaction and what acceptance of an HSA/FSA payment means for your own account; the advertisement is not an individual eligibility determination.

The oral semaglutide page lists $209 per month for 12 months, $239 for six, $259 for three and $279 for one. Oral tirzepatide lists $269, $289, $309 and $339 per month for those respective durations. Because their table labels are inconsistent, obtain a corrected quote before using those figures to compare routes. The homepage also displays the annual $99 offer alongside “This offer has ended,” leaving its current availability unresolved.

05What changes after the first payment?

Homepage fine print makes renewal a separate question from the initial plan price. One note advertises $199 per month for the first six months, a claimed $540 saving, followed by renewal at $1,734 for six months, equivalent to $289 per month. Another advertises $139 per month initially, a claimed $360 saving, then $1,194 per six months, equivalent to $199 per month. Their relationship to every promotional card is not fully resolved.

The plans page additionally advertises savings of $360 for six-month semaglutide and $270 for its three-month option; for tirzepatide, it advertises $540 and $270 respectively. These are provider claims, not independently calculated savings here. A separate $25 discount applies to the first prescribed treatment, requires consultation and is subject to eligibility. Ask whether it combines with your selected offer and request both the first charge and subsequent renewal charge in writing.

Cancellation and refunds remain less clearly documented. Older terms allow a membership pause through the secure account or support@heandshemd.com, and say an on-demand period of eight consecutive weeks without a continuation visit may lead to cancellation without notice. Current plans advertise no membership fees, so those clauses cannot confidently be treated as the current GLP-1 policy. Obtain the cancellation deadline, refund boundaries and effect on prepaid treatment before committing; renewal questions can help structure that request.

06What is included, and what must you arrange separately?

The plans page says every plan includes medication if prescribed, injection supplies, free shipping, ongoing provider support and unlimited messaging, without membership fees. Those inclusions are useful, but ask which apply to the exact product you select, especially an oral or branded option. A purchase covering a stated duration does not by itself establish how much medication arrives in each shipment or whether an entire annual supply is sent at once.

He & She MD does not accept insurance, provide superbills or communicate with insurers. It says patients may independently submit receipts after paying directly, but reimbursement is not guaranteed. That is different from an insurance-supported prescribing service that handles claims or coverage communication. NIDDK notes that coverage varies by plan, so a receipt-submission possibility should not be treated as an expected reduction in the amount you must pay.

The site promotes an app for following progress and adjusting the plan, alongside nutrition guidance and habit coaching. It does not establish whether laboratory work is included, the schedule for clinical reassessment or professional availability in Spanish. Ask who reviews progress, how changes are authorized and whether any additional encounters carry separate fees. NIDDK describes follow-up as attention to response and tolerability, not merely another payment or automatic shipment.

07Which pharmacy ships your prescription, and when?

The site names Specialty Medical Drugstore LLC, doing business as GoGoMeds, and F&F Pharmacies Inc, doing business as Jungle Jim’s Pharmacy, as fulfillment partners. That identifies dispensing relationships, not necessarily who prepares each compounded formulation. The FAQ says Jungle Jim’s holds licenses in 44 states but also lists ten excluded states and says it cannot dispense sterile compounds. The public explanation does not reconcile those numerical and operational limitations.

Those listed exclusions are California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia and Delaware. Separately, He & She MD advertises GLP-1 shipping to every U.S. state except Louisiana, no PO-box deliveries and discreet packaging. Ask which pharmacy would serve your state and specific prescription. The broad shipping statement does not independently confirm prescribing availability, pharmacy coverage or fulfillment of every formulation in every advertised state.

A process graphic presents a two-to-three-day delivery stage, with tracking emailed after prescribing, but does not clearly define when that clock begins. The homepage advertises free expedited shipping; an educational article says medication, syringes and instructions usually ship cold-packed. Neither establishes a guaranteed arrival date. FDA advises not using an injectable GLP-1 product that arrives warm or insufficiently refrigerated and contacting the provider or dispensing pharmacy. Our delivery questions address practical handoff details.

08What does ongoing support mean in practice?

The injectable semaglutide page advertises 24/7 support, while the plans page promises unlimited messaging and ongoing provider support. The telemedicine consent establishes an important boundary: asynchronous services are not emergency services, and personal data will not be monitored around the clock. Continuous access to a messaging channel is therefore not the same as continuous clinician surveillance, an immediate reply or emergency coverage.

Ask who receives a message first, how to reach the prescribing practice, what response window applies and which channel should handle an urgent medication concern. The consulted documentation does not establish guaranteed response times or clinician working hours. For measurement or administration questions, seek instructions from the prescriber or pharmacist rather than calculating from an online review. FDA has received reports of compounded-medication measurement and administration errors, some involving hospitalization; those reports are not a He & She MD event rate.

Privacy also depends on the channel. Although the commercial FAQ broadly describes encryption, the terms explicitly warn that text messages and emails are not encrypted and may be intercepted. Ask which secure portal to use for sensitive information and what communications arrive through ordinary email or SMS. The app and messaging promises may be useful features, but their practical value depends on staffing, escalation and communication boundaries that should be explained before enrollment.

Questions & answers

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

1. FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
2. NIDDK: prescription medications for overweight and obesity ↗
3. He & She MD — prescription weight loss medication ↗
4. He & She MD — weight loss/plans ↗
5. He & She MD — weight loss/semaglutide oral ↗
6. He & She MD — terms of service ↗
7. He & She MD — official website ↗
8. He & She MD — what to expect when starting a compounded semaglutide program ↗
9. He & She MD — weight loss/tirzepatide injection ↗
10. He & She MD — weight loss/tirzepatide oral ↗
11. He & She MD — weight loss/semaglutide injection ↗

Continue reading

• What Does a GLP-1 Program Need to Explain Before You Enroll?
• Ask What the Medicine Is Before Comparing the Offer
• Ten GLP-1 Price Questions Beyond “How Much per Month?”
• What to Ask About GLP-1 Shipping—and What to Do When a Delivery Goes Wrong
• Questions to Settle Before the Next GLP-1 Program Charge